Rabeprazole · Aciphex, Aciphex Sprinkle

What is Rabeprazole?

Rabeprazole is a substituted benzimidazole proton pump inhibitor. It is converted in the acidic parietal cell canaliculus to an active sulfenamide that covalently binds cysteine residues of the gastric H+/K+ ATPase, blocking the final step of gastric acid secretion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Aciphex, Aciphex Sprinkle

Drug type

Small molecule

Targets

H+/K+ ATPase (gastric proton pump) (ATP4A)

Mechanism

Inhibitor of H+/K+ ATPase (gastric proton pump) (ATP4A)

Pathways

gastric acid secretion

Therapy area

Gastroenterology

Developer

Waylis Therap

In trials of

ALMS

FDA status

Approved as Aciphex, Aciphex Sprinkle (August 19, 1999), NDA020973 · FDA label

✅ FDA-approved uses

• Gastroesophageal Reflux Disease (GERD), erosive or ulcerative, healing and maintenance (Aciphex)
• Symptomatic GERD (Aciphex)
• Duodenal ulcer healing (Aciphex)
• Helicobacter pylori eradication to reduce duodenal ulcer recurrence (Aciphex)
• Pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (Aciphex)

From the indications section of the FDA label (version of Jan 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pharmacokinetics

Other drugs acting on ATP4A

Sources

• FDA label (DailyMed)
• FDA label Aciphex (2026-01-27), indications
• NCI Thesaurus

Updated Oct 11, 2026.